Alexion recalls some Soliris batches

The US-only recall amounts to less than 1% of the company's inventory.

J&J posts third-quarter progress

J&J posts third-quarter progress


The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.

Boehringer shutters problematic Ohio plant

1,100 workers will lose their jobs at a plant with a history of around 40 recalls.

Business Briefs: GSK, Astellas, Vertex and Orexigen

GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.

Business briefs: Élan, Teva

A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys.

J&J OTC sales slipped 3% in 2012 worldwide


CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.

J&J says no shakeup at McNeil Consumer Healthcare unit


J&J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.

Email Newsletters